ValuEngine upgraded shares of Nantkwest (NASDAQ:NK) from a hold rating to a buy rating in a research note released on Thursday.
NK has been the topic of a number of other reports. Citigroup cut Nantkwest to a hold rating and set a $3.00 target price on the stock. in a report on Friday, August 10th. Zacks Investment Research upgraded Nantkwest from a hold rating to a buy rating and set a $4.25 target price on the stock in a report on Wednesday, October 10th. Finally, BidaskClub upgraded Nantkwest from a sell rating to a hold rating in a report on Friday, September 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $3.63.
Shares of NK stock traded up $0.03 during mid-day trading on Thursday, hitting $2.47. 2,411 shares of the stock traded hands, compared to its average volume of 360,204. Nantkwest has a twelve month low of $2.16 and a twelve month high of $5.47. The stock has a market cap of $193.27 million, a PE ratio of -1.98 and a beta of 3.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.45 and a current ratio of 5.45.
In related news, Director Steve Gorlin sold 21,475 shares of Nantkwest stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $3.06, for a total value of $65,713.50. Following the transaction, the director now directly owns 224,805 shares in the company, valued at approximately $687,903.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 72.30% of the company’s stock.
Institutional investors have recently modified their holdings of the company. A.R.T. Advisors LLC acquired a new stake in Nantkwest during the first quarter valued at $119,000. JPMorgan Chase & Co. boosted its position in Nantkwest by 40.9% during the first quarter. JPMorgan Chase & Co. now owns 46,068 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 13,366 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Nantkwest by 40.5% during the second quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock valued at $521,000 after purchasing an additional 49,040 shares during the last quarter. Millennium Management LLC boosted its position in Nantkwest by 402.4% during the first quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock valued at $610,000 after purchasing an additional 125,544 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Nantkwest by 144.2% during the second quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 127,694 shares during the last quarter. 13.55% of the stock is owned by institutional investors and hedge funds.
Nantkwest Company Profile
NantKwest, Inc engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S.
Read More: Marijuana Stocks Future Looks Bright
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.